Panageas et al. ( 1 ) recently showed that progression-free survival (PFS) is dependent on the assessment schedule; the same is true of time to progression (TTP). Other factors that may affect TTP include: 1) whether it is measured from diagnosis, randomization, or first dose; 2) whether progression is defined by investigator assessment or a consistently applied algorithm; and 3) different qualities of response. Paradoxically, in clinical trials of treatment for multiple myeloma (MM), a high complete response (CR) rate may result in a shorter-thanexpected median TTP, an observation that is inconsistent with the greater clinical benefit typically associated with CR.
In multiple myeloma, changes in the level of serum and urine M-protein are the basis for assessing response to therapy and monitoring disease evolution. The European Group for Blood and Marrow Transplantation ( 2 ) defi nes a CR, in part, as an immunofi xation-negative, 100% decrease in M-protein in both serum and urine, and it defi nes relapse from CR as reappearance of M-protein on immunofi xation. This strict defi nition of relapse could lead to a paradoxically shorter remission duration in patients achieving CR than in those achieving a partial response (PR; ≥ 50% to <100% decrease in M-protein), with progression from PR requiring a greater than 25% increase in M-protein, which must also be at least 5 g/L ( 2 ). Relapse from CR and progression are defi ned events in Kaplan -Meier analyses of TTP/PFS. However, as noted in the International Uniform Response Criteria for Multiple Myeloma ( 3 ), such "events," particularly relapse from CR, may not correspond with true symptomatic relapse; therefore, reporting of time to next treatment is suggested ( 3 ), which refl ects the clinical benefi t of a prolonged TTP requiring intervention associated with CR.
As an illustration of the limitations of TTP as an endpoint in multiple myeloma, we examined data from a subset analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions trial in relapsed multiple myeloma patients ( 4 ) that were recently presented at the International Myeloma Workshop ( 5 ) . In this updated analysis of the 331 bortezomib-treated patients, TTP was similar in patients achieving CR and in those achieving PR. In contrast, time to next therapy (fi rst dose of bortezomib to fi rst dose of next anti-MM therapy) and treatment-free interval (last dose of bortezomib to fi rst dose of next anti-MM therapy), which refl ect clinical benefi t, were substantially longer in patients achieving CR than in those attaining only PR (27.1 vs 14.0 months and 24.1 vs 6.4 months, respectively) ( 5 ).
These data add to the considerations raised by Panageas et al. ( 1 ) when interpreting PFS/TTP in cancer trials and support the notion that, in multiple myeloma trials, TTP "per se" may not truly refl ect the overall clinical benefi t of therapy. Clinicians should be aware that shorter-than-expected TTP may in fact be associated with longer time to next therapy or treatment-free interval; therefore, caution should be exercised when interpreting TTP and comparing these results across trials. What may in fact be more important to patients is time off therapy, which is better refl ected by measuring time to next therapy or treatment-free interval. This is particularly important with novel agents such as bortezomib, which is known for achieving high rates of CR, in turn a critical parameter of clinical benefi t associated with improved overall survival ( 6 ). 
